Every 10-Q that CAVITATION TECHS INC (CVAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CVAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVAT filings page.
Cavitation Technologies, Inc. reported sharply weaker results and continuing financial strain for the quarter and nine months ended March 31, 2026. Quarterly revenue fell to $3,000 from $122,000, and nine‑month revenue dropped to $6,000 from $198,000, mainly because prior‑year sales tied to vegetable oil refining patents did not recur.
The company posted a net loss of $219,000 for the quarter and $953,000 for the nine months, compared with prior‑year nine‑month net income of $122,000 that was boosted by an $880,000 patent assignment gain. Cash declined to $45,000, with a stockholders’ deficit of $467,000, an 8% related‑party promissory note of $91,000, a net 8% convertible note balance of $28,000, and a $150,000 SBA EIDL loan outstanding.
The company’s auditors previously raised substantial doubt about its ability to continue as a going concern, and management again acknowledges this risk, noting it believes existing cash only supports operations through June 2026 absent new financing or higher revenue. After quarter‑end, Cavitation received a binding letter of intent from European Guarantee Services S.à. to acquire 100% of Cavitation and its affiliates in an all‑cash deal valuing the business at $40–$42 million, or about $0.13 per share on a fully diluted basis. The proposal remains subject to due diligence, a definitive agreement, a fairness opinion, shareholder approval, and regulatory clearances, including a potential CFIUS review; proof of funds was delivered on April 8, 2026.
Cavitation Technologies, Inc. reported a sharp downturn for the quarter ended December 31, 2025. Revenue fell to $0 from $76,000 a year earlier as prior-period Nano Reactor® sales tied to patents sold to Desmet did not repeat. Operating expenses rose to $474,000, driven mainly by higher stock-based compensation, leading to an operating loss of $474,000.
There was no repeat of the prior-year $880,000 gain on patent assignment, so the company swung from net income of $579,000 to a net loss of $476,000 for the quarter, and a $734,000 loss for the six months. Cash declined to $31,000, total assets were $55,000, and stockholders’ deficit was $248,000, while liabilities totaled $303,000.
The 10-Q highlights substantial doubt about the company’s ability to continue as a going concern, citing continuing operating losses, limited cash, and reliance on raising additional capital and executing new revenue initiatives in water treatment, agriculture, beverage technology, hydro-plasma, and its new Xyra crypto-related subsidiary. As of February 13, 2026, 309,720,740 common shares were outstanding.
Cavitation Technologies (CVAT) filed its Form 10‑Q, reporting Q1 fiscal 2026 results for the three months ended September 30, 2025. Revenue was $3,000 from a short‑term equipment rental. Operating expenses were $252,000, driving a loss from operations of $249,000. Interest expense rose to $9,000 after reconciling its SBA EIDL loan, resulting in a net loss of $258,000.
Cash used in operations was $219,000, leaving $30,000 in cash at quarter‑end. Total assets were $60,000 against total liabilities of $249,000, producing a stockholders’ deficit of $(189,000). The company had 289,156,340 common shares outstanding as of November 12, 2025. Management and the auditor highlighted substantial doubt about going concern. Debt consisted of a non‑current $150,000 EIDL note at 3.75%. Warrants outstanding totaled 49,041,323 (weighted‑average exercise price $0.053). Disclosure controls and procedures were deemed not effective. Management cites licenses in water/wastewater and beverages and ongoing trials as potential future revenue drivers.